Patents by Inventor Carlos J. Gimeno
Carlos J. Gimeno has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20020115140Abstract: The present invention relates, first, to the identification of novel nucleic acid molecules, termed RATH genes and RATH gene products encoded by such nucleic acid molecules, or degenerate variants thereof, that participate in the regulation, control and/or modulation of G-protein-mediated signal transduction involved in T cell activation, including, but not limited to T helper (TH) cell and TH cell subpopulation activation. Specifically, the nucleic acid molecules of the present invention include the genes corresponding to the mammalian RATH genes, including the RATH1.1 genes. Sequence analysis indicates that the RATH genes are novel genes belonging to the RGS (“regulator of G-protein signalling”) gene family, a gene family which encodes gene products involved in G-protein-mediated signal transduction.Type: ApplicationFiled: June 4, 2001Publication date: August 22, 2002Applicant: Millennium Pharmaceuticals, Inc.Inventors: Douglas Adam Levinson, Carlos J. Gimeno
-
Patent number: 6399760Abstract: The present invention, which is based on the discovery of novel genes encoding rp polypeptides, features therapeutics, diagnostics and screening assays.Type: GrantFiled: August 29, 1996Date of Patent: June 4, 2002Assignee: Millennium Pharmaceuticals, Inc.Inventors: Carlos J. Gimeno, Patrick W. Kleyn, Karen J. Moore
-
Patent number: 6291177Abstract: The invention relates to a novel transformed yeast cell comprising a first heterologous nucleic acid sequence encoding a G-protein coupled receptor; and second nucleic acid sequence encoding the yeast G&agr; subunit protein Gpa2; and an optional third heterologous nucleic acid sequence encoding a reporter protein. The G-protein coupled receptor can bind ligand thereby altering the activity of Gpa2 and cellular levels of second messenger molecules and ultimately the activity of target genes. The transformed yeast cell can be used, for example, in in vitro high throughput assays to screen for agonists and antagonists of G-protein coupled receptor ligand activity.Type: GrantFiled: August 6, 1999Date of Patent: September 18, 2001Assignee: Millennium Pharmaceuticals, Inc.Inventors: Kevin T. Madden, Patrick R. Errada, Carlos J. Gimeno
-
Patent number: 6280934Abstract: The invention relates to a novel transformed yeast cell comprising a first heterologous nucleic acid sequence encoding a G-protein coupled receptor; and second nucleic acid sequence encoding the yeast G&agr; subunit protein Gpa2; and an optional third heterologous nucleic acid sequence encoding a reporter protein. The G-protein coupled receptor can bind ligand thereby altering the activity of Gpa2 and cellular levels of second messenger molecules and ultimately the activity of target genes. The transformed yeast cell can be used, for example, in in vitro high throughput assays to screen for agonists and antagonists of G-protein coupled receptor ligand activity.Type: GrantFiled: May 13, 1998Date of Patent: August 28, 2001Assignee: Millennium Pharmaceuticals, Inc.Inventors: Kevin T. Madden, Patrick R. Errada, Carlos J. Gimeno
-
Patent number: 6146827Abstract: The present invention relates, first, to the identification of novel nucleic acid molecules, termed RATH genes and RATH gene products encoded by such nucleic acid molecules, or degenerate variants thereof, that participate in the regulation, control and/or modulation of G-protein-mediated signal transduction involved in T cell activation, including, but not limited to T helper (TH) cell and TH cell subpopulation activation. Specifically, the nucleic acid molecules of the present invention include the genes corresponding to the mammalian RATH genes, including the RATH1.1 genes. Sequence analysis indicates that the RATH genes are novel genes belonging to the RGS ("regulator of G-protein signalling") gene family, a gene family which encodes gene products involved in G-protein-mediated signal transduction.Type: GrantFiled: October 10, 1997Date of Patent: November 14, 2000Assignee: Millennium Pharmaceuticals, Inc.Inventors: Douglas Adam Levinson, Carlos J. Gimeno
-
Patent number: 6147192Abstract: The present invention provides a novel tub interactor (TI) polypeptides, as well as TI fusion polypeptides, and antigenic peptides.Type: GrantFiled: February 18, 1999Date of Patent: November 14, 2000Assignee: Millennium Pharmaceuticals, Inc.Inventors: Carlos J. Gimeno, Patrick R. Errada
-
Patent number: 6031076Abstract: The present invention relates to the discovery of novel conservin genes and polypeptides. Therapeutics, diagnostics and screening assays based on these molecules are also disclosed.Type: GrantFiled: January 5, 1998Date of Patent: February 29, 2000Assignee: Millenium Pharmaceuticals, Inc.Inventors: Dean A. Falb, Carlos J. Gimeno
-
Patent number: 6020142Abstract: The present invention relates, first, to the identification of novel nucleic acid molecules, termed RATH genes and RATH gene products encoded by such nucleic acid molecules, or degenerate variants thereof, that participate in the regulation, control and/or modulation of G-protein-mediated signal transduction involved in T cell activation, including, but not limited to T helper (TH) cell and TH cell subpopulation activation. Specifically, the nucleic acid molecules of the present invention include the genes corresponding to the mammalian RATH genes, including the RATH1.1 genes. Sequence analysis indicates that the RATH genes are novel genes belonging to the RGS ("regulator of G-protein signalling") gene family, a gene family which encodes gene products involved in G-protein-mediated signal transduction.Type: GrantFiled: June 6, 1997Date of Patent: February 1, 2000Assignee: Millennium Pharmaceuticals, Inc.Inventors: Douglas Adam Levinson, Carlos J. Gimeno
-
Patent number: 6008014Abstract: The present invention relates to the discovery of novel genes encoding Lipid Metabolic Pathway (LMP) polypeptides. Therapeutics, diagnostics and screening assays based on these molecules are also disclosed.Type: GrantFiled: September 4, 1996Date of Patent: December 28, 1999Assignee: Millennium Pharmaceuticals, Inc.Inventors: Carlos J. Gimeno, Susan Acton
-
Patent number: 5955306Abstract: The present invention relates to the discovery of novel genes encoding Tub interactor (TI) polypeptides. Therapeutics, diagnostics and screening assays based on these molecules are also disclosed.Type: GrantFiled: July 21, 1997Date of Patent: September 21, 1999Assignee: Millenium Pharmaceuticals, Inc.Inventors: Carlos J. Gimeno, Patrick R. Errada
-
Patent number: 5948639Abstract: The invention provides isolated nucleic acids molecules, designated EMI1 nucleic acid molecules, which encode proteins involved in growth factor, e.g., TGF-.beta., cell signaling. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing EMI1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an EMI1 gene has been introduced or disrupted. The invention still further provides isolated EMI1 proteins, fusion proteins, antigenic peptides and anti-EMI1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: April 10, 1997Date of Patent: September 7, 1999Assignee: Millennium Pharmaceuticals, Inc.Inventors: Carlos J. Gimeno, Dean A. Falb
-
Patent number: 5846780Abstract: The present invention relates, first, to the identification of novel nucleic acid molecules and proteins encoded by such nucleic acid molecules, or degenerate variants thereof, that participate in the regulation, control and/or modulation of G-protein-mediated signal transduction involved in T cell activation, including, but not limited to T helper (TH) cell and TH cell subpopulation activation. Specifically, the nucleic acid molecules of the present invention include the genes corresponding to the mammalian R11 gene, including the human R11 gene. R11 sequence analysis indicates that the R11 gene is a novel gene belonging to the RGS ("regulator of G-protein signalling") gene family, a gene family which encodes gene products involved in G-protein-mediated signal transduction.Type: GrantFiled: October 4, 1996Date of Patent: December 8, 1998Assignee: Millennium Pharmaceuticals, Inc.Inventors: Douglas Adam Levinson, Carlos J. Gimeno
-
Patent number: 5807708Abstract: The present invention relates to the discovery of novel conservin genes and polypeptides. Therapeutics, diagnostics and screening assays based on these molecules are also disclosed.Type: GrantFiled: July 30, 1996Date of Patent: September 15, 1998Assignee: Millennium Pharmaceuticals, Inc.Inventors: Dean A. Falb, Carlos J. Gimeno